Drug intelligence / Profile preview

SLV-404

Development stage: Preclinical
Lead developer: Solve Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SLV-404 is an antibody-drug conjugate (ADC) under preclinical development for the treatment of Richter's syndrome, a type of lymphoma. The drug targets two mechanisms: it acts as an antagonist to receptor-like tyrosine kinase (RYK) and as an inhibitor of DNA topoisomerase I (Top I). By combining these actions, SLV-404 aims to disrupt cancer cell signaling and DNA replication, potentially leading to anti-tumor effects. The drug is being developed by Solve Therapeutics in collaboration with the University of Turin[2][6].

Targets

RYK (Receptor-like tyrosine kinase)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on SLV-404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLV-404.

Explore the full profile